Karl Keegan

Head of Research

About

Karl has worked in the Life Sciences sector for over 25 years and has covered a number of impressive stocks and transactions during his career, including the $1 billion IPO of Serono on the New York Stock Exchange as well as the IPO of Genmab (which was the largest IPO in Europe at the time).

Karl values the opportunity to combine his scientific knowledge with his capital markets expertise to provide actionable ideas to our institutional clients as well as helping our corporate clients develop a compelling equity story.

Outside of work, Karl enjoys long distance swimming and volunteers for road safety charities as an advanced motorcycle instructor.

Key Highlights

Over 25 Years

of industry expertise

Breadth of Career

has combined academic, capital markets, & corporate executive roles

Member

of the Capital Markets Advisory Committee